Lisa A. Beck, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-7546

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Research Labs

Visit Lab Website

Locations

University of Rochester Medical Center
Ambulatory Center - 2nd Floor (AC2)
601 Elmwood Ave
Rochester, NY 14642

URMC Dermatology
400 Red Creek Dr
Suite 200
Rochester, NY 14623

Faculty Appointments

Professor - Department of Dermatology (SMD)
Lowell A. and Carol A. Goldsmith Professor in Dermatology - Department of Dermatology (SMD)
Professor - Department of Pathology and Laboratory Medicine (SMD) - Joint
Professor - Department of Medicine , Allergy/Immunology and Rheumatology (SMD) - Joint

Patient Care Setting

Dermatology

Biography

Dr. Beck brings more than 20 years' experience to the treatment of atopic dermatitis and eczema. She is currently involved in an NIH-funded study to determine why certain patients are susceptible to the herpes simplex and Staphylococcus aureus viruses. Dr. Beck received her undergraduate degree from Mount Holyoke College and her medical degree from the State University of New York at Stony Brook.

Research

Dr. Lisa Beck has dedicated her 25 year career to finding safe, effective treatments for patients with atopic dermatitis, more commonly known as eczema. Internationally recognized as an eczema expert, her research was instrumental in the development of the first biologic drug called dupilumab (brand name Dupixent) for the treatment of adults with moderate to severe eczema. She was the lead author of a 2014 New England Journal of Medicine paper that set the stage for the FDA approval of this drug in March 2017. She is Co-Director of the URMC Center for Allergic Disease Research (CADR) which was recently chosen as one of four US centers with the World Allergy Organizations Center of Excellence designation. She has been the secretary of the International Eczema Council (IEC) since its inception in 2014, emeritus member of the National Eczema Association (NEA) Scientific Advisory committee, and President-Elect of the Society of Investigative Dermatology. She has been NIH-funded to study this disease since 1992 and her main focus is now on understanding why certain eczema patients are susceptible to cutaneous viral infections such as herpes simplex as well as bacterial colonization or infection with Staphylococcus aureus. As the founding director of the URMC Dermatology Clinical Trials Unit, she has completed >14 clinical AD registry, mechanistic, and interventional trials, all of which met or exceeded enrollment/retention expectations and has > 500 person URMC AD patient Registry. She has had continuous NIH funding since 1994, and has been co-PI of the NIH/NIAID-funded Atopic Dermatitis Research Network (ADRN) since it inception in 2004, which has amassed the largest cross-sectional registry of deeply phenotyped AD subjects in the world. She has been PI of the ADRN Biomarker Repository since 2014 with >150,000 serum and skin swab samples. Dr. Beck received her undergraduate degree from Mount Holyoke College, her medical degree from the State University of New York at Stony Brook, two years of internal medicine training at Strong Memorial Hospital, Dermatology residency at Duke University and an Immunology Research fellowship at Johns Hopkins University.

Credentials

Education

1985
MD | Stony Brook University Hospital (USA)

Post-doctoral Training & Residency

07/01/1987 - 07/31/1990
Residency in Dermatology at Duke University Medical Center

07/01/1986 - 07/31/1987
Residency in Internal Medicine at University of Rochester Medical Center

06/27/1985 - 07/31/1986
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL

Awards

2008
Dermatology Faculty Teaching Award
Sponsor: University of Rochester Medical Center

2007
Mentor for NEASE Skin Research Grant Recipient
Sponsor: NEASE

2007
Mentor for AAAAI Summer Research Grant Recipient
Sponsor: AAAAI

2006
Mentor for Astellas Skin Research Grant Recipient
Sponsor: Astellas

2005
Mentor for Fujisawa AAAAI Research Grant Recipient
Sponsor: Fujisawa

1997
Mentor for Howard Hughes Summer Fellowship Recipient
Sponsor: Howard Hughes

1994
Physician-Scientist Award
Sponsor: National Institute of Health

1994
Research Award
Sponsor: Dermatology Foundation

1992
Teaching Appreciation Award
Sponsor: Johns Hopkins University
Location: Dermatology Department

1992
Internal Medicine Teaching Award
Sponsor: Francis Scott Key Medical Center

VIEW ALL

Clinical Trials

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12)

Lead Researcher: Lisa A Beck

This is a study which will characterize the gene expression profiles that underlie mild and moderate-severe Atopic dermatitis (AD). It will determine changes in these expression patterns in response to standard-of-care treatment. Participants will complete up to ten study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles that underlie mild vs. moderate-severe atopic dermatitis. Healthy participants without atopic dermatitis will serve as a control population and must agree to apply a topical moisturizer (Vanicream) at least twice daily for 7 days. Atopic dermatitis patients must have chronic AD with active lesions.

View Study Details

Patents

Patent Title: System and Method for Studying Epidermis Samples Ex Vivo
Patent #: 8,993,257
Issue Date: Mar 31, 2015
Country: United States
Invented By: Lisa A Beck, Anna De Benedetto

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: 3033108
Issue Date: Mar 24, 2021
Country: Europe
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: FR3033108
Issue Date: Mar 24, 2021
Country: France
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: DE3033108
Issue Date: Mar 24, 2021
Country: Germany
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: IT3033108
Issue Date: Mar 24, 2021
Country: Italy
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: ES3033108
Issue Date: Mar 24, 2021
Country: Spain
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: GB3033108
Issue Date: Mar 24, 2021
Country: United Kingdom
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: ZL 201480052086.0
Issue Date: Jun 02, 2020
Country: China, People's Republic of
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: 9,757,428
Issue Date: Sep 12, 2017
Country: United States
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin Locke Miller

VIEW ALL

Publications

Journal Articles

8/24/2023
Moran MC, Klose A, Yoshida T, De Benedetto A, Schneider LC, Ong PY, Simpson EL, Leung DYM, Miller BL, Seplaki CL, Beck LA. "History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis." Dermatology and therapy.. 2023 Aug 24; Epub 2023 Aug 24.

8/1/2023
Guttman-Yassky E, Silverberg JI, Thaçi D, Papp KA, Ständer S, Beck LA, Kim BS, Hu X, Liu J, Calimlim BM, Vigna N, Crowley JT, Teixeira HD, Thyssen JP. "Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial." Journal of the European Academy of Dermatology and Venereology : JEADV.. 2023 Aug 1; Epub 2023 Aug 01.

6/19/2023
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. "Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study." Journal of the European Academy of Dermatology and Venereology : JEADV.. 2023 Jun 19; Epub 2023 Jun 19.

Books & Chapters

2008
Chapter Title: Update on the Managment of Atopic Dermatitis
Book Title: Allergy Frontiers: Epigenetics to Future Perspectives
Author List: Ibrahim SF, DeBenedetto A, Beck LA
Edited By: Pawankar R, Holgate S, Rosenwasser L
Published By: Springer 2008 in Tokyo, Japan

2007
Chapter Title: Regulation of the Production and Activation of Eosinophils and Neutrophils
Book Title: Dermatology in General Medicine
Author List: Beck LA, Loveless J, Holland S
Edited By: Freedberg I, Katz S, Wolff K, Eisen A, Austen KF and Goldsmith L
Published By: McGraw-Hill Co. 2007 in New York

2004
Chapter Title: Regulation of the Production and Activation of Eosinophils
Book Title: Dermatology In General Medicine
Author List: Rencic A, Beck LA
Edited By: Freedburg I, Eisen A, Wolff K, Austen KF, Goldsmith L, and Katz SI
Published By: Mc-Graw-Hill Co. 2004 in New York

VIEW ALL PUBLICATIONS